Elsevier

Virology

Volume 349, Issue 1, 25 May 2006, Pages 41-54
Virology

Interaction of small molecule inhibitors of HIV-1 entry with CCR5

https://doi.org/10.1016/j.virol.2006.01.018Get rights and content
Under an Elsevier user license
open archive

Abstract

The CC-chemokine receptor 5 (CCR5) is the major coreceptor for macrophage-tropic (R5) HIV-1 strains. Several small molecule inhibitors of CCR5 that block chemokine binding and HIV-1 entry are being evaluated as drug candidates. Here we define how CCR5 antagonists TAK-779, AD101 (SCH-350581) and SCH-C (SCH-351125), which inhibit HIV-1 entry, interact with CCR5. Using a mutagenesis approach in combination with a viral entry assay to provide a direct functional read out, we tested predictions based on a homology model of CCR5 and analyzed the functions of more than 30 amino acid residues. We find that a key set of aromatic and aliphatic residues serves as a hydrophobic core for the ligand binding pocket, while E283 is critical for high affinity interaction, most likely by acting as the counterion for a positively charged nitrogen atom common to all three inhibitors. These results provide a structural basis for understanding how specific antagonists interact with CCR5, and may be useful for the rational design of new, improved CCR5 ligands.

Keywords

GPCR
CCR5
CCR5 inhibitors
HIV-1
TAK-779
AD101
SCH-C

Cited by (0)

1

Present affiliation: Avance Pharma Inc., Laval, Quebec, Canada H7V 5B7.